HealthInternational

Chinese Vaccine Barely Effective, Far Worse than First Claimed

A coronavirus vaccine developed by Beijing-based Sinovac Biotech Ltd., was barely 50% effective during late-stage clinical trials in Brazil, significantly less than earlier results reported, a statement from the city government of Sao Paulo said Tuesday.

Previous announcements indicated Sinovac Biotech’s vaccine performed at a rate of 78% overall efficacy. By comparison, the FDA-approved vaccines from Pfizer-BioNTech and Moderna boast rates of 95% and 94.5%, respectively.

“The Butantan Institute and the government of Sao Paulo report that the coronavirus vaccine achieved a 50.38% overall efficacy rate in the clinical study conducted in Brazil, in addition to (an efficacy rate of) 78% for mild cases and 100% for moderate and severe cases of COVID-19,” the statement said, CNN reported. “All rates are higher than the 50% level required by the World Health Organization.”

The dip of 78% to 50.38% has raised questions among public health experts about the veracity of the Sinovac Biotech’s data and fuels skepticism over the transparency of Chinese virus vaccines.

Top members of the Brazilian Health Ministry said the Sinovac Biotech’s vaccine’s “effectiveness is borderline” and that is because it was “at the limit,” they would need to wait for the evaluation by ANVISA, the country’s health regulatory agency, CNN’s local affiliate reported.

Sinovac Biotech defended its vaccine Wednesday, saying the differing efficacy rates are “the results from different populations, in different places with different mobility rates, and therefore they span a relatively large range.”

The final vaccine efficacy rate will be decided by China’s drug regulator, the National Medical Production Administration, CNN reported.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Back to top button

My News Matters to me - Washington Informer Donations

Be a Part of The Washington Informer Legacy

A donation of your choice empowers our journalists to continue the work to better inform, educate and empower you through technology and resources that you use.

Click Here Today to Support Black Press and be a part of the Legacy!

Subscribe today for free and be the first to have news and information delivered directly to your inbox.

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Adblock Detected

Please consider supporting us by disabling your ad blocker